BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18936884)

  • 1. Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
    Saeki T; Okita A; Aogi K; Kakishita T; Okita R; Taira N; Ohama Y; Takashima S; Nishikawa K
    Breast Cancer; 2009; 16(2):113-20. PubMed ID: 18936884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
    Sakurai K; Matsuo S; Enomoto K; Amano S; Shiono M
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1994-6. PubMed ID: 20037302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R; Osaki A; Toge T
    Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
    Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
    Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
    Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
    Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase I study of NK 622 (toremifene citrate)].
    Tominaga T; Hayashi K; Hayasaka A; Asaishi K; Abe R; Kimishima I; Izuo M; Iino Y; Yokoe T; Abe O
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2363-72. PubMed ID: 1463343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
    Camacho LH; Kurzrock R; Cheung A; Barber DF; Gupta S; Madoff DC; Wallace MJ; Kim EE; Curley SA; Hortobagyi GN; Mavligit G
    Cancer; 2007 Jun; 109(11):2190-6. PubMed ID: 17464952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of metastatic breast cancer responding to weekly paclitaxel and high-dose toremifene administrated alternately].
    Murakami H; Noda S; Okamura Y; Sakakibara T; Ishikawa T; Nakamura H; Yaguchi T; Harada A
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1963-6. PubMed ID: 12465396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
    Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
    Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.